CH20 CH20 CH20 CH20 CH20 CH20 | Premium Research-Grade Beauty Peptide |Chonluten| 99% Purity | Lyophilized Powder | High Quality | Retatrutide

(4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Glu-Asp-Gly;glutamyl-aspartyl-glycine;H-Glu-Asp-Gly-OH;T-34 tripeptide;Glu-asp-gly;Glutamyl-aspartyl-glycine;75007-24-8;(4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;H-Glu-asp-gly-OH;T-34 tripeptide;L-Glutamyl-L-aspartyl-glycine;SCHEMBL3909775;DTXSID80996513;CHEBI:162780;Glycine, N-(N-L-alpha-glutamyl-L-alpha-aspartyl)-;4-Amino-5-({3-carboxy-1-[(carboxymethyl)imino]-1-hydroxypropan-2-yl}imino)-5-hydroxypentanoic acid

75007-24-8

C11H17N3O8

DSPQRJXOIXHOHK-WDSKDSINSA-N

319.27 g/mol

319.10156451 g/mol

Bulk Drug Intermediates

196 Ų

-1.1791

143 - 145 °C

Triple agonist — GCGR, GIPR, GLP-1R

Investigational (Phase 3)

Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

5.79 nM

0.191 nM

0.794 nM

2.32 nM

0.775 nM

0.0643 nM

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

NCT04881760; NCT05882045; NCT06354660

CHEMBL5095485

DB18993

D12430

PubChem

NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.